Eortc MoBilE Device (EMBED) – Implementation of smart devices for the assessment of Quality of Life, Patient Reported Outcomes (PROs) and physical functioning and activity in EORTC clinical trials: A feasibility study
Project summary
The EMBED project aims at building the first blocks of an implementation strategy for the incorporation of HRQoL measurements into the world of digital health and telemedicine in cancer patients and to prepare the EORTC and the QLG to face the emergence of these new technologies in the field of cancer clinical trials. More precisely, EMBED will target the following objectives:
Main objective:
Developing an EORTC QLG strategy for the capture, through digital solutions, of HRQoL and objective patient measures, including physical activity.
Secondary objectives:
- Identifying the existing methodologies using mobile devices for the assessment of HRQoL in cancer patients and assessing their feasibility
- Assessing the feasibility of implementing mobile devices for the assessment of physical activity in the context of EORTC clinical trials, identifying its major human and operational factors
- Exploring the potential added value of using mobile devices for the assessment of physical activity in the context of EORTC clinical trials and its associations with HRQoL data
Achievements
The EMBED project started in January 2024. The systematic review (WP1) and the writing of the field study protocol (WP2) are in progress.
Current status:
Protocol writing (WP2)
Future plans
Protocol release (WP2) – November 2024
First site active – Q1 2025
First patient recruited – Q2 2025
For patients
While the idea of using new technologies such as smartphones for assessing the quality of life of patients with cancer becomes more and more widespread, the EORTC currently has limited experience in this field. The goal of the EMBED project is to identify the pros and cons of using these technologies in the context of cancer clinical trials by 1) collecting information in the scientific literature (WP1) and 2) asking cancer patients who will participate to a study using new technologies to describe their own experience (WP2).